This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BLCM Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM) 30 days 90 days 365 days Advanced Chart Get BLCM alerts:Sign Up Key Stats Today's Range$0.07▼$0.0950-Day Range$0.07▼$0.1052-Week Range$0.06▼$1.31Volume6,059 shsAverage Volume22,874 shsMarket Capitalization$726,570.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Read More… Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCM Stock News HeadlinesBellicum Pharmaceuticals Inc (BLCM)April 16, 2025 | uk.investing.comBellicum Pharmaceuticals Inc (OTC:BLCM) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.May 4, 2025 | Paradigm Press (Ad)Bellicum sells assets to MD Anderson, moves towards liquidationFebruary 22, 2024 | msn.comBellicum Pharmaceuticals Issues Super-Voting Share PrivatelyJanuary 25, 2024 | msn.comBellicum Pharmaceuticals Inc BLCMDecember 23, 2023 | morningstar.comBellicum Pharmaceuticals Stock (OTC:BLCM), Short Interest ReportDecember 8, 2023 | benzinga.comFutura Medical plc (FAMDF)October 27, 2023 | finance.yahoo.comSee More Headlines BLCM Stock Analysis - Frequently Asked Questions How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its quarterly earnings data on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter. When did Bellicum Pharmaceuticals' stock split? Bellicum Pharmaceuticals shares reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Bellicum Pharmaceuticals IPO? Bellicum Pharmaceuticals (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), CyberArk Software (CYBR), Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY). Company Calendar Last Earnings8/11/2021Today5/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BLCM CIK1358403 Webwww.bellicum.com Phone(281) 454-3424FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,970,000.00 Net MarginsN/A Pretax Margin-1,492.40% Return on EquityN/A Return on Assets-157.93% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio3.04 Sales & Book Value Annual Sales$1.50 million Price / Sales0.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book0.33Miscellaneous Outstanding Shares9,720,000Free Float8,716,000Market Cap$726,570.00 OptionableNot Optionable Beta1.39 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:BLCM) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellicum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.